156 related articles for article (PubMed ID: 30302127)
1. Drug holiday in patients with polycystic liver disease treated with somatostatin analogues.
van Aerts RMM; Kolkman M; Kievit W; Gevers TJG; Nevens F; Drenth JPH
Therap Adv Gastroenterol; 2018; 11():1756284818804784. PubMed ID: 30302127
[TBL] [Abstract][Full Text] [Related]
2. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.
Gevers TJ; Inthout J; Caroli A; Ruggenenti P; Hogan MC; Torres VE; Nevens F; Drenth JP
Gastroenterology; 2013 Aug; 145(2):357-65.e1-2. PubMed ID: 23665274
[TBL] [Abstract][Full Text] [Related]
3. Questionnaire PLD-complaint-specific assessment identifies need for therapy in polycystic liver disease: A multi-centric prospective study.
Billiet A; Temmerman F; Coudyzer W; Van den Ende N; Colle I; Francque S; De Maeght S; Janssens F; Orlent H; Sprengers D; Delwaide J; Decock S; De Vloo C; Moreno C; van Malenstein H; van der Merwe S; Verbeek J; Nevens F
United European Gastroenterol J; 2023 Sep; 11(7):633-641. PubMed ID: 37278135
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials.
Neijenhuis MK; Gevers TJ; Nevens F; Hogan MC; Torres VE; Kievit W; Drenth JP
Aliment Pharmacol Ther; 2015 Sep; 42(5):591-8. PubMed ID: 26129925
[TBL] [Abstract][Full Text] [Related]
5. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH;
Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403
[TBL] [Abstract][Full Text] [Related]
6. Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.
Gevers TJ; Nevens F; Torres VE; Hogan MC; Drenth JP
Liver Int; 2016 Apr; 36(4):595-602. PubMed ID: 26481454
[TBL] [Abstract][Full Text] [Related]
7. Severity in polycystic liver disease is associated with aetiology and female gender: Results of the International PLD Registry.
van Aerts RMM; Kievit W; de Jong ME; Ahn C; Bañales JM; Reiterová J; Nevens F; Drenth JPH
Liver Int; 2019 Mar; 39(3):575-582. PubMed ID: 30225933
[TBL] [Abstract][Full Text] [Related]
8. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis.
Griffiths J; Mills MT; Ong AC
BMJ Open; 2020 Jan; 10(1):e032620. PubMed ID: 31924636
[TBL] [Abstract][Full Text] [Related]
9. The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials.
Garofalo C; Capuano I; Pennino L; De Gregorio I; Riccio E; Provenzano M; Crocetto F; Buonanno P; Pandolfo SD; Andreucci M; Pisani A
Sci Rep; 2021 Dec; 11(1):23500. PubMed ID: 34873228
[TBL] [Abstract][Full Text] [Related]
10. The long-term outcome of patients with polycystic liver disease treated with lanreotide.
Chrispijn M; Nevens F; Gevers TJ; Vanslembrouck R; van Oijen MG; Coudyzer W; Hoffmann AL; Dekker HM; de Man RA; van Keimpema L; Drenth JP
Aliment Pharmacol Ther; 2012 Jan; 35(2):266-74. PubMed ID: 22111942
[TBL] [Abstract][Full Text] [Related]
11. Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis.
Sierks D; Schönauer R; Friedrich A; Hantmann E; de Fallois J; Linder N; Fischer J; Herber A; Bergmann C; Berg T; Halbritter J
JHEP Rep; 2022 Nov; 4(11):100579. PubMed ID: 36246085
[TBL] [Abstract][Full Text] [Related]
12. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP
J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726
[TBL] [Abstract][Full Text] [Related]
13. Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease.
Temmerman F; Ho TA; Vanslembrouck R; Coudyzer W; Billen J; Dobbels F; van Pelt J; Bammens B; Pirson Y; Nevens F
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2353-9.e1. PubMed ID: 26073493
[TBL] [Abstract][Full Text] [Related]
14. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
16. Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease.
Chebib FT; Jung Y; Heyer CM; Irazabal MV; Hogan MC; Harris PC; Torres VE; El-Zoghby ZM
Nephrol Dial Transplant; 2016 Jun; 31(6):952-60. PubMed ID: 26932689
[TBL] [Abstract][Full Text] [Related]
17. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
Hogan MC; Masyuk TV; Page LJ; Kubly VJ; Bergstralh EJ; Li X; Kim B; King BF; Glockner J; Holmes DR; Rossetti S; Harris PC; LaRusso NF; Torres VE
J Am Soc Nephrol; 2010 Jun; 21(6):1052-61. PubMed ID: 20431041
[TBL] [Abstract][Full Text] [Related]
18. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
Hogan MC; Chamberlin JA; Vaughan LE; Waits AL; Banks C; Leistikow K; Oftsie T; Madsen C; Edwards M; Glockner J; Kremers WK; Harris PC; LaRusso NF; Torres VE; Masyuk TV
Clin J Am Soc Nephrol; 2020 Sep; 15(9):1267-1278. PubMed ID: 32843370
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies.
Ma L; Luo D; Yang T; Wu S; Li M; Chen C; Zhou S; Ma L; Wu Y; Zhou Y; Cui Y
BMC Endocr Disord; 2020 Aug; 20(1):126. PubMed ID: 32811475
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial.
D'Agnolo HM; Kievit W; Takkenberg RB; Riaño I; Bujanda L; Neijenhuis MK; Brunenberg EJ; Beuers U; Banales JM; Drenth JP
J Hepatol; 2016 Sep; 65(3):601-7. PubMed ID: 27212247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
